Table 1.
The baseline clinical data of 584 subjects
| Characteristics | HCC (n = 190) | LC (n = 114) | CHB (n = 120) | Health (n = 160) |
|---|---|---|---|---|
| Age (y) | 52.32 ± 18.63 | 54.65 ± 15.39 | 54.65 ± 15.33 | 52.12 ± 16.76 |
| Male | 136 (71.58) | 76 (66.67) | 84 (70.00) | 110 (68.75) |
| ALT (U/L) | 62.82 ± 46.27 | 71.19 ± 32.40 | 90.81 ± 60.23 | 24.62 ± 16.28 |
| ALB (g/L) | 33.39 ± 14.57 | 30.18 ± 11.95 | 38.13 ± 8.26 | 40.13 ± 4.67 |
| TBIL (μmol/L) | 26.54 ± 19.83 | 76.49 ± 42.35 | 50.28 ± 46.03 | 9.81 ± 6.73 |
| PLT (×109/μL) | 15.65 ± 13.07 | 11.36 ± 9.81 | 16.85 ± 13.49 | 19.04 ± 10.27 |
| HBeAg (+) | 96 (50.52) | 60 (52.63) | 68 (56.67) | 0 (0) |
| HBV DNA (log10 copies/mL) | 5.93 ± 1.86 | 5.78 ± 1.29 | 5.87 ± 1.13 | 0 |
| AFP (≥20 ng/L) | 118 (62.11) | 62 (54.39) | 32 (26.67) | 0 (0) |
There were significant differences in the levels of ALT, ALB, TBIL, PLT and AFP in the HCC, LC and CHB groups (P < 0.05). All data are presented as mean ± standard deviation or n (%)
HCC hepatocellular carcinoma, LC liver cirrhosis, CHB chronic hepatitis B; ALT alanine aminotransferase, ALB albumin, TBIL total bilirubin, PLT blood platelet, HBeAg HBV e-antigen, AFP α-fetoprotein